Form 4: Casdin Partners Boosts Stake in Standard BioTools

Casdin Partners Master Fund, L.P. and affiliated entities increased their beneficial ownership in Standard BioTools Inc. through recent stock purchases.

Summary

• Casdin Partners Master Fund, L.P. acquired a total of 925,000 shares of Standard BioTools Inc. common stock across three transactions in November 2025.
• On November 13, 2025, 450,000 shares were purchased at a weighted average price of $1.2031 per share, with prices ranging from $1.1978 to $1.2098.
• On November 14, 2025, an additional 250,000 shares were acquired at a weighted average price of $1.2392 per share, with prices ranging from $1.2364 to $1.2434.
• On November 17, 2025, 225,000 shares were bought at a weighted average price of $1.2248 per share, with prices ranging from $1.2175 to $1.2299.
• Following these transactions, Casdin Partners Master Fund, L.P. indirectly beneficially owns 62,975,000 shares.
• Eli Casdin directly owns 2,901,062 shares.
• Casdin Private Growth Equity Fund II, L.P. indirectly owns 13,939,637 shares.
• Casdin Private Growth Equity Fund, L.P. indirectly owns 2,744,219 shares.
• Eli Casdin, as managing member of Casdin Capital, LLC and Casdin Partners GP, LLC, is deputized to represent the Reporting Persons on the Issuer's board of directors, leading to all associated reporting persons being deemed directors for Section 16 purposes.

Sentiment

Score: 8

Explanation: The significant insider buying by a major institutional investor and director suggests strong confidence in the company's valuation and future prospects, which is generally a positive signal for investors.

Positives

• Significant insider buying by a major shareholder and director, indicating strong confidence in the company's future prospects.
• The purchases were made at prices ranging from $1.1978 to $1.2434, suggesting a belief in value at these levels.
• Increased alignment of interests between a major institutional investor/director and other shareholders.

Future Outlook

NA

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

NA

Corporate Governance

Related Party Transactions

• Casdin Partners Master Fund, L.P., an entity affiliated with director Eli Casdin and a 10% owner, purchased shares of Standard BioTools Inc. common stock.

Stakeholder Impact

• Shareholders: Potentially positive, as significant insider buying can signal confidence and value, which may lead to increased share price stability or appreciation.
• Management: Increased alignment with a major institutional investor and director.

Key Dates

Recommendation

The significant insider buying by Casdin Partners and its affiliates, who are also 10% owners and deemed directors, indicates strong conviction in Standard BioTools Inc.'s current valuation and future prospects. This action suggests that a well-informed party sees value at these price levels. However, without broader financial context from earnings reports or strategic updates, a 'hold' recommendation is prudent. Investors should view this as a positive signal but combine it with a deeper fundamental analysis before making a 'buy' decision.

Keywords

STANDARD BIOTOOLS INC., LAB, Casdin Partners, Insider Buying, Form 4, Beneficial Ownership, Equity Purchase, Director Transaction, 10% Owner, Stock Acquisition